Outlook Therapeutics, Inc.
General ticker "OTLK" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $58.1M (TTM average)
Outlook Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -13.7%.
Estimated limits based on current volatility of 8.3%: low 1.42$, high 1.67$
Factors to consider:
- Total employees count: 17 as of 2025
- Top business risk factors: Insufficient capital, Product development failure, Manufacturing disruptions, Regulatory and compliance, Labor/talent shortage/retention
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-09-30 to 2027-09-30
- 2025-09-30 to 2026-09-30 estimated range: [0.91$, 2.90$]
- 2026-09-30 to 2027-09-30 estimated range: [0.54$, 1.85$]
Financial Metrics affecting the OTLK estimates:
- Positive: with PPE of -0.5 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of 0 > -0.60
- Positive: Interest expense per share per price, % of 0.82 <= 3.34
Short-term OTLK quotes
Long-term OTLK plot with estimates
Financial data
| YTD | 2023-09-30 | 2024-09-30 | 2025-09-30 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $1.41MM |
| Operating Expenses | $53.13MM | $71.70MM | $68.48MM |
| Operating Income | $-53.13MM | $-71.70MM | $-67.06MM |
| Non-Operating Income | $-5.85MM | $-3.66MM | $3.08MM |
| Interest Expense | $2.53MM | $3.16MM | $0.28MM |
| R&D Expense | $26.45MM | $41.76MM | $27,180,640.00MM |
| Income(Loss) | $-58.98MM | $-75.36MM | $-63.98MM |
| Taxes | $0.00MM | $0.00MM | $-1.55MM |
| Net Income(Loss)* | $-58.98MM | $-75.37MM | $-62.42MM |
| Stockholders Equity | $-14.44MM | $-73.08MM | $-32.19MM |
| Inventory | $0.00MM | $0.00MM | $3.34MM |
| Assets | $32.30MM | $28.82MM | $18.58MM |
| Operating Cash Flow | $-42.97MM | $-68.79MM | $-51.83MM |
| Financing Cash Flow | $48.97MM | $60.33MM | $44.98MM |
| Earnings Per Share** | $-4.72 | $-4.06 | $-1.79 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.